Influence of endothelin receptor antagonism on smooth muscle cell proliferation after chronic renal failure

Journal of Cardiovascular Pharmacology

Volumn 44, Issue SUPPL. 1, 2004, Pages

  Sauter, Gabriele ^a   Wolf, Sabine ^a   Risler, Teut ^a   Brehm, Bernhard ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Medizinische Klinik III   (Germany)

Author keywords

Endothelin; Proliferation; Smooth muscle cells; Uremia

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BROXURIDINE; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; LU 302146; PLATELET DERIVED GROWTH FACTOR BB; UNCLASSIFIED DRUG;

ANIMAL CELL; CELL CULTURE; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; MALE; MUSCLE CELL; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; UREMIA; VASCULAR SMOOTH MUSCLE;

ANIMALS; BENZHYDRYL COMPOUNDS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLAST GROWTH FACTOR 2; KIDNEY FAILURE, CHRONIC; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEPHRECTOMY; PLATELET-DERIVED GROWTH FACTOR; PROPIONIC ACIDS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; TIME FACTORS;

EID: 11144349733     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000166245.28368.ae     Document Type: Conference Paper

References (11)

1. Foley RN, Parfrey PS, Samak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(Suppl. 12): S16-S23.
2. Cheung AK, Samak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353-362.
3. Ritz E, Koomans HA. New insights into mechanisms of blood pressure regulation in patients with uraemia. Nephrol Dial Transplant. 1996;11 (Suppl. 2):52-59.
4. Larivière R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol. 2003;81:607-621.
5. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
6. Lindner V, Lappi DA, Baird A, et al. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res. 1991;68:106-113.
7. Brehm BR, Wolf SC, Bertsch D, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001;49:430-439.
8. Brehm BR, Klaussner M, Wolf SC. Chronic elevated endothelin-1 concentrations regulate mitogen-activated protein kinases ERK 1 and ERK 2 in vascular smooth muscle cells. Clin Sci (Lond). 2002;103 (Suppl. 48):S137-S140.
9. Hirata Y, Takagi Y, Fukuda Y, et al. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989;78:225-228.
10. Jahan H, Kobayashi S, Nishimura J, et al. Endothelin-1 and angiotensin II act as progression but not competence growth factors in vascular smooth muscle cells. Eur J Pharmacol. 1996;295:261-269.
11. Yang Z, Krasnici N, Lüscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF. Effects of ETA and ETB receptor blockade. Circulation. 1999;100:5-8.